查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1832438

大肠直肠癌药物市场（按药物类别、通路、给药途径、治疗线、目标分子和治疗环境划分）—全球预测 2025-2032

Colorectal Cancer Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Line Of Therapy, Target Molecule, Treatment Setting - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，大肠直肠癌药物市场规模将成长至 171.7 亿美元，复合年增长率为 5.29%。

主要市场统计数据
基准年2024年 113.6亿美元
预计2025年 119.5亿美元
预测年份：2032年 171.7亿美元
复合年增长率（%） 5.29%

简要说明复杂的结直肠癌治疗生态系统，重点关注精准医疗、获取动态和策略重点领域

大肠直肠癌仍然是临床上最复杂、商业性最具活力的癌症领域之一，其驱动力来自快速发展的科学认知和不断扩展的治疗工具。本执行摘要总结了影响治疗模式的临床、监管和商业性趋势，尤其关注标靶治疗、免疫肿瘤学和组合方案的创新如何重新定义治疗标准。引言部分从以患者为中心的疗效以及研发方、支付方和医疗服务提供者的战略需求两个视角来阐述现状，并强调了生物标誌物主导的治疗选择与日益精细的安全性和有效性计算之间的相互作用。

随着诊断能力的提升和精准医疗在实践中的日益融合，大肠直肠癌治疗的连续性正从「一刀切」的细胞毒性方案转向更个人化的方案。这种转变为临床差异化和商业性价值获取创造了新的机会，同时也要求临床开发、真实世界证据生成和付款人参与之间更加紧密地协调。引言部分概述了本研究的分析范围以及贯穿报告始终的关键主题：创新、可及性、成本控制压力以及在异质医疗保健系统之间实施复杂方案的营运挑战。

分子分层、新型治疗方法和不断发展的给药模式如何重塑结直肠治疗的临床路径和商业性重点

由于分子标靶、免疫调节和递送技术的突破，结直肠癌治疗方法正在经历深刻变化。在临床层面，基于生物标记的分层方法日益成熟，使得治疗方法的使用更加精准，例如针对特定分子组使用EGFR定向药物，以及针对错配修復缺陷型肿瘤使用免疫查核点抑制剂。同时，包括过继性细胞疗法和重组生技药品在内的新型治疗方法正从早期临床开发阶段发展到旨在克服原发性和后天性抗药性机制的探索性联合治疗。这些进展正在重塑临床路径，透过增加治疗方案的复杂性并扩大个人化治疗方案的范围。

从商业性角度来看，付款人和医疗保健提供者正在重新调整其采购和报销方式，以便在传统的化疗基础上，同时兼顾高成本的专科药物。随着相关人员寻求在快速患者可及性和上市后证据生成之间取得平衡，真实世界证据计划和管理准入协议 (MAR) 正变得越来越普遍。此外，口服标靶治疗和皮下生物製药的激增正在影响药物的分销和倡议策略，并推动医疗机构和门诊环境中医疗服务管理方式的转变。总而言之，这些动态正在创造一个新的竞争格局，那些能够展示差异化临床价值、实用的交付模式以及在日常实践中持续效用的可靠证据的开发商将获得丰厚回报。

美国近期关税对医药供应链、筹资策略和抗癌药物取得途径的影响

美国2025年实施的最新贸易和关税政策，为全球医药供应链带来了额外的复杂性，并对肿瘤治疗药物的采购、定价策略和跨境分销产生了具体影响。製造商和经销商正在重新评估筹资策略原料药和最终产品的采购策略，力求透过本地生产、供应多元化和重新协商物流合约来降低关税带来的成本风险。此类营运调整对于依赖紧密协调的全球供应链的注射用生技药品和复杂的小分子化合物尤其明显。

同时，医疗系统和药局网路也不得不调整其合约方式，以在控制预算限制的同时维持病患的用药管道。在某些情况下，采购商加快了多年期协议的签订，或探索了基于价值的合约结构，以稳定净成本并确保供应的连续性。在临床层面，处方集委员会在评估新进者时，更加重视治疗相容性通讯协定和总照护成本。因此，供应链的弹性和商业性敏捷性正变得越来越重要。能够确保供应、对冲关税影响并在创新准入机制上合作的公司，在贸易政策不确定时期更有能力保持竞争的连续性。

综合治疗层级、通路、给药途径和分子标靶的细分观点将为临床和商业策略提供资讯。

细分市场动态揭示了清晰的临床和营运重点，这些重点为涵盖治疗层级、通路、给药途径、治疗线、标靶分子和治疗环境的产品定位、研究设计和商业化策略提供资讯。按药物类别划分，化疗将继续保持其基本相关性，Fluoropyrimidines、铂类化合物和拓扑异构酶抑制剂将成为许多治疗方案的标准支柱；而免疫疗法将随着针对免疫反应性和持久性反应的查核点抑制剂和过继性细胞疗法而扩展。单株抗体策略将专注于表皮生长因子受体抑制剂和血管内皮生长因子抑制剂，以实现靶向的细胞外阻断；而小分子抑制剂将专注于透过BRAF抑制剂、MEK抑制剂和蛋白酪氨酸激酶抑製剂进行细胞内信号传导调控，以解决特定的致癌驱动因素。

在各个分销管道中，医院药房仍然是住院患者输液和复杂联合通讯协定的核心，而零售和线上专业药房越来越多地采用口服标靶药物和皮下製剂，以提高便利性和依从性。给药途径持续影响临床工作流程和病人偏好。虽然静脉治疗在急性护理中占主导地位，但口服药物可以实现门诊给药和家庭依从性模式，而皮下製剂则提供了提高临床效率和患者舒适度的机会。第一线药物的核准需要证明良好的结果和耐受性，而第二线和三线治疗方案通常强调分子定义或难治性族群的反应。从分子角度来看，表皮生长因子受体、程序性细胞死亡蛋白 1 (PDP-1)、程序性死亡配体 1 (PDL-1) 和血管内皮生长因子 (VGF) 正受到越来越多的关注，每种因子都影响伴随诊断和联合策略。不同的住院和门诊护理环境会影响资源分配、给药时间表和提供者培训需求。透过整合这些细分镜头，开发人员和付款人可以将临床价值提案与实际交付考虑相结合，并优先产生引起决策者共鸣的证据。

全球主要地区的监管、付款人和基础设施差异如何影响大肠直肠护理的取得途径和采用模式

区域驱动因素差异显着，并正在塑造美洲、欧洲、中东和非洲以及亚太地区的临床实践模式、监管重点和商业性准入策略。在美洲，监管改革和成熟的精准肿瘤学基础设施正在支持生物标誌物主导疗法的快速应用，而付款人审查和价值框架则奖励强有力的证据包和管理准入解决方案。这种区域环境有利于那些提供明确疗效差异化和与现实世界疗效相关的实用准入途径的申办方。

在欧洲、中东和非洲，集中监管指导与各国报销体系的差异化相互作用，推动着市场进入策略的精细化，其中早期参与卫生技术评估和价格谈判至关重要。此外，一些市场的产能限制正在影响那些需要专业医疗基础设施的复杂治疗方法的采用速度。在亚太地区，监管时间表的不均衡以及肿瘤学领域投资的不断增长，导致采用节奏参差不齐。一些市场迅速接受了口服标靶治疗和本地化製造投资，而另一些市场则优先考虑具有成本效益的疗法和可扩展的交付模式。总体而言，区域策略必须在独特的付款人预期、基础设施准备情况以及支持永续取得和证据产生的伙伴关係模式之间取得平衡。

多相关人员综合药物开发、伴随诊断和合作商业化方法的竞争动态

大肠直肠癌领域的竞争态势体现了大型跨国製药公司、专业肿瘤生物技术公司、诊断开发公司和合约服务供应商的混合格局，它们各自为治疗方法的进步和商业化做出了独特的贡献。大型製药公司利用其开发资源和全球商业化网络来支持后期项目和跨区域上市，通常透过将新型药物与成熟的化疗药物相结合来展现出更佳的疗效。专业生物技术公司则推动利基治疗方法（例如细胞疗法和高选择性激酶抑制剂）的创新，专注于快速迭代、生物标记主导的试验设计以及加速临床验证的策略伙伴关係。

诊断开发商正成为竞争定位的核心，他们提供的伴随检测能够实现标靶药物输送，并提升精准医疗的临床效用。同时，受託製造厂商以及专业分销合作伙伴为复杂的生物製药和新型药物产品提供营运基础设施，支援其规模化生产和灵活的供应策略。协作开发模式正转向共同开发和数据共用，使临床终点与付款人相关的结果保持一致。整合诊断、精简生产和可执行证据计划的公司更有可能获得更高的市场接受度和持续的临床差异化优势。

製药和生物技术领导者应采取策略行动，协调创新、供应弹性和以付款人为中心的证据生成，以实现持续的治疗成功

针对行业领导者的可行建议包括：将临床创新与切实可行的可及性途径相结合，并专注于营运韧性，以应对不断变化的结直肠癌形势。首先，优先考虑与监管机构和相关人员进行早期和反覆的沟通，制定兼顾临床和现实世界有效性的循证计划，并开展包含与决策者相关的终点和亚组的关键临床试验。其次，在进行治疗方案的同时，投资伴随诊断的开发，以确保及时识别患者，并透过精准用药强化价值概念。

第三，透过区域製造选项、策略性库存缓衝以及关键投入的多元化采购，建构供应链弹性，以降低贸易政策波动和物流中断带来的风险。第四，设计反映给药途径和护理环境的商业化模式，利用专科药房和门诊病人配送伙伴关係关係，提供口服和皮下製剂，同时保持医院管道对复杂输液方案的支持。最后，推进协作数据倡议，并实施基于价值的合约试点，以展示成果并与付款人共用风险，加快药物可及性，同时基于可衡量的患者效益建立差异化。

一种严谨的多源资讯来源研究途径，结合临床文献、监管更新、专家意见和现实世界证据，阐明治疗和获取的动态

本执行摘要所依据的研究整合了同行评审的临床文献、监管指南文件、已发表的临床试验结果、行业科学通讯以及公开的治疗指南，旨在构建全面均衡的结直肠癌治疗格局。研究重点是将关键临床试验报告的临床结果与后续的真实世界分析进行交叉引用，以便在对照试验环境之外对转化医学的疗效进行实用评估。透过近期的核准通知、附加檔更新和公共咨询委员会的审议，分析了监管趋势，以明确不断变化的证据预期。

补充定性资讯源自专家医生评论和付款人政策声明，旨在识别不同医疗保健系统中的应用机会和障碍。透过考察製造足迹、通路动态和贸易政策沟通，评估了供应链和商业性准入的考量。调查方法和资料来源的严谨性体现在：对多个独立资讯来源进行三角测量，以获得关键论点；尽可能优先考虑原始资料；以及透明地记录需要证据产生的持续临床不确定性领域。

整合临床创新和业务需求，强调综合证据、诊断一致性和弹性存取策略

总而言之，随着分子标靶疗法、免疫疗法的不断扩展以及治疗模式的不断发展，结直肠癌的治疗格局正在迅速改变，这些都增加了更个人化治疗的可能性。然而，这些科学进步也与实际挑战并存，包括供应链的韧性、付款人的期望以及在不同医疗环境中提供复杂治疗方案的营运需求。因此，要取得持续的临床和商业性成功，需要製定整合策略，将差异化的证据产生、切实可行的可近性解决方案和稳健的营运规划相结合。

相关人员若能将产品开发与伴随诊断结合，透过以结果为导向的证据预测支付方需求，并提升供应和分销的灵活性，就最有能力将治疗创新转化为持久的病患利益。随着情况的不断发展，开发商、诊断供应商、支付方和医疗保健提供者之间的持续合作对于将科学进步转化为大肠直肠癌患者可及且有效的治疗途径至关重要。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合液态生物检体生物标记检测，实现大肠直肠癌个人化治疗
  • 推出双特异性抗体疗法，旨在增强大肠直肠癌的免疫治疗反应
  • 转移性大肠直肠癌新型抗EGFR药物的监管核准现状
  • 扩大口服氟嘧啶疗法以提高大肠直肠癌治疗患者的便利性
  • 增加对大肠直肠肿瘤微环境的微生物组调节疗法的投资
  • 多标靶蛋白酪氨酸激酶抑制剂治疗大肠直肠癌的临床研究进展

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 大肠直肠癌药物市场（依药物类别）

  • 化疗
    • Fluoropyrimidines
    • 铂化合物
    • 拓朴异构酶抑制剂
  • 免疫疗法
    • 过继性细胞疗法
    • 查核点抑制剂
  • 单株抗体
    • 表皮生长因子受体抑制剂
    • 血管内皮生长因子抑制剂
  • 小分子抑制剂
    • BRAF抑制剂
    • MEK抑制剂
    • 蛋白酪氨酸激酶抑制剂

9. 大肠直肠癌药物市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 10 章：按给药途径分類的结直肠癌药物市场

  • 静脉
  • 口服
  • 皮下

第11章 大肠直肠癌药物市场（依治疗线）

  • 初级治疗
  • 二级处理
  • 三级处理

第十二章 大肠直肠癌药物市场（以标靶分子）

  • 表皮生长因子受体
  • 程序性细胞死亡蛋白1
  • 程序性死亡配体1
  • 血管内皮生长因子

第 13 章：大肠直肠癌药物市场（依治疗环境）

  • 住院病人
  • 门诊

第 14 章：大肠直肠癌药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章 大肠直肠癌药物市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 大肠直肠癌药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
    • Amgen Inc.
    • Amneal Pharmaceuticals, Inc.
    • Apotex Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline PLC
    • HUTCHMED（China）Limited
    • Lupin Limited
    • Mallinckrodt Pharmaceuticals
    • Manus Aktteva Biopharma LLP
    • Marksans Pharma Ltd.
    • Merck & Co., Inc.
    • Mylan NV by Viatris Inc.
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi SA
    • Sumitomo Pharma Co., Ltd.
    • Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • VolitionRx Limited
Product Code: MRR-431B7BFFBF56

The Colorectal Cancer Drugs Market is projected to grow by USD 17.17 billion at a CAGR of 5.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.36 billion
Estimated Year [2025] USD 11.95 billion
Forecast Year [2032] USD 17.17 billion
CAGR (%) 5.29%

A concise orientation to the complex colorectal cancer treatment ecosystem highlighting precision therapeutics, access dynamics, and strategic focus areas

Colorectal cancer remains one of the most clinically complex and commercially dynamic oncology areas, driven by rapidly evolving scientific understanding and a widening therapeutic toolbox. This executive summary synthesizes clinical, regulatory, and commercial developments shaping treatment paradigms, with particular attention to how innovation in targeted agents, immuno-oncology, and combination regimens is redefining standards of care. The introduction positions the landscape through the dual lenses of patient-centric outcomes and strategic imperatives for developers, payers, and providers, highlighting the interplay between biomarker-driven treatment selection and an increasingly nuanced safety-efficacy calculus.

As diagnostic capabilities advance and precision medicine becomes more embedded in practice, the continuum of care for colorectal cancer is shifting from one-size-fits-all cytotoxic regimens to more individualized approaches. This transition generates new opportunities for clinical differentiation and commercial value capture, while also demanding tighter alignment across clinical development, real-world evidence generation, and payer engagement. The introduction closes by outlining the scope of the analysis and the principal thematic threads that recur throughout the report: innovation, access, cost-management pressures, and the operational challenges of bringing complex regimens to heterogeneous health systems.

How molecular stratification, novel modalities, and evolving delivery models are reshaping clinical pathways and commercial priorities in colorectal therapeutics

The therapeutic landscape for colorectal cancer is experiencing transformative shifts driven by breakthroughs in molecular targeting, immune modulation, and delivery technologies. At the clinical level, the maturation of biomarker stratification is enabling more precise use of therapies such as EGFR-directed agents for defined molecular cohorts and immune checkpoint inhibitors for mismatch repair-deficient tumors. Concurrently, novel modalities including adoptive cell therapies and engineered biologics are progressing from early clinical development into exploratory combinations that aim to overcome primary and acquired resistance mechanisms. These developments are reshaping clinical pathways by expanding options for personalized sequences of care while also increasing regimen complexity.

From a commercial perspective, payers and providers are recalibrating procurement and reimbursement approaches to accommodate high-cost specialty agents alongside conventional chemotherapy backbones. Real-world evidence initiatives and managed entry agreements are becoming more prevalent as stakeholders seek to balance rapid patient access with evidence generation post-launch. Furthermore, the proliferation of oral targeted therapies and subcutaneous biologics is influencing distribution and adherence strategies, prompting shifts in how institutions and outpatient settings manage therapy delivery. Collectively, these dynamics are creating new competitive dimensions that reward developers who can demonstrate differentiated clinical value, pragmatic delivery models, and robust evidence of sustained benefit in routine practice.

Implications of recent United States tariff measures on pharmaceutical supply chains, procurement strategies, and access pathways for oncology therapies

Recent trade and tariff policies implemented within the United States in 2025 introduced incremental complexity to global pharmaceutical supply chains, with tangible implications for procurement, pricing strategies, and cross-border distribution of oncology therapeutics. Manufacturers and distributors have responded by re-evaluating sourcing strategies for active pharmaceutical ingredients and finished products, seeking to mitigate tariff-driven cost exposure through localized manufacturing, supply diversification, and renegotiated logistics contracts. These operational adjustments are particularly salient for injectable biologics and complex small molecule inputs that depend on tightly coordinated global supply chains.

In parallel, health systems and pharmacy networks have had to adjust contracting approaches to preserve patient access while managing budgetary constraints. In some cases, purchasers accelerated multi-year agreements or explored value-based contracting structures to stabilize net costs and ensure continuity of supply. At the clinical level, formulary committees are placing greater emphasis on therapeutic interchange protocols and total cost of care considerations when evaluating new entries. The net effect is a heightened importance of supply chain resilience and commercial agility; companies that can demonstrably secure supply, hedge tariff exposure, and partner on innovative access mechanisms are better positioned to maintain competitive continuity during periods of trade policy uncertainty.

Integrated segmentation perspectives across therapeutic classes, distribution pathways, administration routes, and molecular targets to inform clinical and commercial strategies

Segment-level dynamics reveal distinct clinical and operational priorities that inform product positioning, trial design, and commercialization tactics across therapeutic classes, distribution channels, routes of administration, lines of therapy, target molecules, and treatment settings. By drug class, chemotherapy maintains foundational relevance with fluoropyrimidines, platinum compounds, and topoisomerase inhibitors continuing as standard backbones for many regimens, while immunotherapy expands through checkpoint inhibitors and adoptive cell therapies that target immune responsiveness and durable benefit. Monoclonal antibody strategies concentrate on epidermal growth factor receptor inhibitors and vascular endothelial growth factor inhibitors, delivering targeted extracellular blockade, whereas small molecule inhibitors emphasize intracellular signaling control via BRAF inhibitors, MEK inhibitors, and tyrosine kinase inhibitors that address specific oncogenic drivers.

Across distribution channels, hospital pharmacies remain central for inpatient infusions and complex combination protocols, while retail pharmacies and online specialty pharmacies increasingly support oral targeted agents and subcutaneous formulations to improve convenience and adherence. Route of administration continues to influence clinical workflow and patient preference: intravenous therapies dominate acute treatment settings, oral agents enable outpatient administration and home-based adherence models, and subcutaneous formulations create opportunities for clinic efficiency and patient comfort. Line of therapy segmentation shapes clinical evidence needs, with first-line approvals demanding demonstration of superior outcomes and tolerability, and second- or third-line positioning often emphasizing response in molecularly defined or refractory populations. From a target molecule perspective, focus areas include epidermal growth factor receptor, programmed cell death protein 1, programmed death ligand 1, and vascular endothelial growth factor, each of which informs companion diagnostics and combination strategies. Treatment setting considerations, differentiated between inpatient and outpatient contexts, affect resource allocation, dosing schedules, and provider training needs. Integrating these segmentation lenses enables developers and payers to align clinical value propositions with practical delivery considerations and to prioritize evidence generation that resonates across decision-makers.

How regional regulatory, payer, and infrastructure differences across major global regions shape access pathways and adoption patterns for colorectal treatments

Regional dynamics vary substantially, shaping clinical practice patterns, regulatory emphasis, and commercial access strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory innovation and established precision oncology infrastructure support rapid uptake of biomarker-driven therapies, while payer scrutiny and value frameworks incentivize robust evidence packages and managed entry solutions. This regional environment favors sponsors that present clear outcomes differentiation and pragmatic access pathways tied to real-world outcomes.

Across Europe, Middle East & Africa, the interplay between centralized regulatory guidance and diverse national reimbursement systems drives nuanced market entry tactics, where early health technology assessment engagement and pricing negotiations are critical. Capacity constraints in some markets also influence the adoption pace of complex modalities that require specialized delivery infrastructure. In the Asia-Pacific region, heterogeneity in regulatory timelines and expanding investments in oncology care are creating mixed adoption rhythms; certain markets demonstrate rapid embrace of oral targeted therapies and localized manufacturing investments, while others prioritize cost-effective interventions and scalable delivery models. Overall, regional strategies must balance localized payer expectations, infrastructure readiness, and partnership models that support sustainable access and evidence generation.

Competitive landscape dynamics driven by integrated drug development, companion diagnostics, and collaborative commercialization approaches among diverse stakeholders

Competitive dynamics in the colorectal cancer space reflect a blend of large multinational pharmaceutical companies, specialized oncology biotechs, diagnostic developers, and contract service providers, each contributing distinct capabilities to therapeutic advancement and commercialization. Large pharmaceutical organizations leverage expansive development resources and global commercialization networks to support late-stage programs and multi-region launches, often pairing novel agents with established chemotherapy backbones to demonstrate incremental benefit. Specialized biotechs drive innovation in niche modalities such as cell therapies and highly selective kinase inhibitors, focusing on rapid iteration, biomarker-driven trial designs, and strategic partnerships to accelerate clinical proof-of-concept.

Diagnostic developers are increasingly central to competitive positioning, supplying companion assays that enable targeted prescribing and enhance the clinical utility of precision agents. Meanwhile, contract development and manufacturing organizations, as well as specialty distribution partners, provide the operational backbone for complex biologics and novel formulations, supporting scale-up and flexible supply strategies. Collaboration patterns are shifting toward co-development and data-sharing arrangements that align clinical endpoints with payer-relevant outcomes, and companies that integrate diagnostics, streamlined manufacturing, and pragmatic evidence plans tend to achieve stronger uptake and sustained clinical differentiation.

Strategic actions for pharmaceutical and biotech leaders to align innovation, supply resilience, and payer-focused evidence generation for durable therapeutic success

Actionable recommendations for industry leaders focus on aligning clinical innovation with pragmatic access pathways and operational resilience to navigate the evolving colorectal oncology environment. First, prioritize early and iterative engagement with regulatory and payer stakeholders to design evidence-generation plans that address both clinical efficacy and real-world effectiveness, ensuring that pivotal trials include endpoints and subgroups relevant to decision-makers. Second, invest in companion diagnostic development alongside therapeutic programs to secure timely patient identification and to strengthen the value narrative through precision use.

Third, build supply chain flexibility through regional manufacturing options, strategic inventory buffers, and diversified sourcing of critical inputs to mitigate exposure to trade policy fluctuations and logistic disruptions. Fourth, design commercialization models that reflect route of administration and care setting, leveraging specialty pharmacy and outpatient delivery partnerships for oral and subcutaneous agents while maintaining hospital channel support for complex infusion regimens. Finally, pursue collaborative data initiatives and value-based contracting pilots to demonstrate outcomes and share risk with payers, thereby accelerating access while creating defensible differentiation based on measurable patient benefit.

A rigorous multi-source research approach combining clinical literature, regulatory updates, expert input, and real-world evidence to contextualize therapeutic and access dynamics

The research underpinning this executive summary synthesizes peer-reviewed clinical literature, regulatory guidance documents, published clinical trial results, company scientific communications, and publicly available treatment guidelines to construct a comprehensive and balanced view of the colorectal cancer therapeutic landscape. Emphasis was placed on cross-referencing clinical outcomes reported in pivotal studies with subsequent real-world analyses where available, enabling a pragmatic assessment of translational performance outside controlled trial settings. Regulatory trends were analyzed through recent approval letters, label updates, and public advisory committee deliberations to identify evolving evidentiary expectations.

Supplementary qualitative inputs were derived from expert physician commentary and payer policy statements to contextualize adoption enablers and barriers across different health systems. Supply chain and commercial access considerations were evaluated by examining manufacturing footprints, distribution channel evolution, and trade policy communications. Throughout, methodological rigor was maintained by triangulating multiple independent sources for key assertions, prioritizing primary data where possible, and transparently noting areas of ongoing clinical uncertainty that warrant targeted evidence generation.

Synthesis of clinical innovation and operational imperatives emphasizing integrated evidence, diagnostics alignment, and resilient access strategies

In conclusion, the colorectal cancer treatment landscape is undergoing rapid transformation driven by molecularly targeted therapies, expanding immunotherapy approaches, and evolving delivery models that collectively enhance the potential for more personalized care. These scientific advances, however, coexist with practical challenges related to supply chain resilience, payer expectations, and the operational demands of delivering complex regimens across diverse care settings. Achieving durable clinical and commercial success will therefore require integrated strategies that link differentiated evidence generation to pragmatic access solutions and robust operational planning.

Stakeholders who align product development with companion diagnostics, anticipate payer needs through outcome-focused evidence, and shore up supply and distribution agility will be best positioned to translate therapeutic innovation into sustained patient benefit. As the landscape continues to evolve, ongoing collaboration among developers, diagnostics providers, payers, and providers will be essential to convert scientific progress into accessible, effective care pathways for patients living with colorectal cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy biomarker testing to personalize colorectal cancer treatment
  • 5.2. Launch of bispecific antibody therapies for enhanced immunotherapeutic response in CRC
  • 5.3. Regulatory approval landscape for new anti-EGFR agents in metastatic colorectal cancer
  • 5.4. Expansion of oral fluoropyrimidine regimens to improve patient convenience in CRC therapy
  • 5.5. Rising investment in microbiome modulation therapies to target colorectal tumor microenvironment
  • 5.6. Clinical pipeline progression of multi-target tyrosine kinase inhibitors for CRC management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colorectal Cancer Drugs Market, by Drug Class

  • 8.1. Chemotherapy
    • 8.1.1. Fluoropyrimidines
    • 8.1.2. Platinum Compounds
    • 8.1.3. Topoisomerase Inhibitors
  • 8.2. Immunotherapy
    • 8.2.1. Adoptive Cell Therapies
    • 8.2.2. Checkpoint Inhibitors
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Epidermal Growth Factor Receptor Inhibitors
    • 8.3.2. Vascular Endothelial Growth Factor Inhibitors
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. BRAF Inhibitors
    • 8.4.2. MEK Inhibitors
    • 8.4.3. Tyrosine Kinase Inhibitors

9. Colorectal Cancer Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Colorectal Cancer Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Colorectal Cancer Drugs Market, by Line Of Therapy

  • 11.1. First Line
  • 11.2. Second Line
  • 11.3. Third Line

12. Colorectal Cancer Drugs Market, by Target Molecule

  • 12.1. Epidermal Growth Factor Receptor
  • 12.2. Programmed Cell Death Protein 1
  • 12.3. Programmed Death Ligand 1
  • 12.4. Vascular Endothelial Growth Factor

13. Colorectal Cancer Drugs Market, by Treatment Setting

  • 13.1. Inpatient
  • 13.2. Outpatient

14. Colorectal Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Colorectal Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Colorectal Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
    • 17.3.2. Amgen Inc.
    • 17.3.3. Amneal Pharmaceuticals, Inc.
    • 17.3.4. Apotex Inc.
    • 17.3.5. Bayer AG
    • 17.3.6. Bristol-Myers Squibb Company
    • 17.3.7. Eisai Co., Ltd.
    • 17.3.8. Eli Lilly and Company
    • 17.3.9. F. Hoffmann-La Roche Ltd
    • 17.3.10. GlaxoSmithKline PLC
    • 17.3.11. HUTCHMED (China) Limited
    • 17.3.12. Lupin Limited
    • 17.3.13. Mallinckrodt Pharmaceuticals
    • 17.3.14. Manus Aktteva Biopharma LLP
    • 17.3.15. Marksans Pharma Ltd.
    • 17.3.16. Merck & Co., Inc.
    • 17.3.17. Mylan N.V. by Viatris Inc.
    • 17.3.18. Novartis AG
    • 17.3.19. Pfizer Inc.
    • 17.3.20. Regeneron Pharmaceuticals, Inc.
    • 17.3.21. Sanofi S.A.
    • 17.3.22. Sumitomo Pharma Co., Ltd.
    • 17.3.23. Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
    • 17.3.24. Takeda Pharmaceutical Company Limited
    • 17.3.25. VolitionRx Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COLORECTAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE COLORECTAL C